BE2016C011I2 - - Google Patents

Info

Publication number
BE2016C011I2
BE2016C011I2 BE2016C011C BE2016C011C BE2016C011I2 BE 2016C011 I2 BE2016C011 I2 BE 2016C011I2 BE 2016C011 C BE2016C011 C BE 2016C011C BE 2016C011 C BE2016C011 C BE 2016C011C BE 2016C011 I2 BE2016C011 I2 BE 2016C011I2
Authority
BE
Belgium
Prior art keywords
hypertension
diabetic
renal
pharmaceutically acceptable
primary
Prior art date
Application number
BE2016C011C
Other languages
English (en)
Dutch (nl)
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of BE2016C011I2 publication Critical patent/BE2016C011I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BE2016C011C 1998-07-10 2016-03-07 BE2016C011I2 (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11389398A 1998-07-10 1998-07-10
EP99934647A EP1096932B1 (en) 1998-07-10 1999-07-09 Antihypertensive combination of valsartan and calcium channel blocker
EP07105179A EP1870098A3 (en) 1998-07-10 1999-07-09 Combined use of valsartan and calcium channel blockers for therapeutic purposes

Publications (1)

Publication Number Publication Date
BE2016C011I2 true BE2016C011I2 (id) 2018-12-04

Family

ID=22352165

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C011C BE2016C011I2 (id) 1998-07-10 2016-03-07

Country Status (31)

Country Link
EP (3) EP1096932B1 (id)
JP (1) JP2002520274A (id)
KR (2) KR20040078140A (id)
CN (2) CN1234357C (id)
AT (1) ATE371448T1 (id)
AU (1) AU753486B2 (id)
BE (1) BE2016C011I2 (id)
BR (1) BR9912021A (id)
CA (2) CA2678722C (id)
CY (4) CY1107779T1 (id)
CZ (2) CZ299429B6 (id)
DE (2) DE69936992T2 (id)
DK (2) DK2322174T3 (id)
ES (2) ES2552639T3 (id)
FR (1) FR16C0008I2 (id)
HU (1) HU229383B1 (id)
ID (1) ID27664A (id)
IL (3) IL140665A0 (id)
LU (2) LU91358I2 (id)
NL (2) NL300290I2 (id)
NO (2) NO331802B1 (id)
NZ (2) NZ527598A (id)
PL (1) PL194604B1 (id)
PT (2) PT2322174E (id)
RU (3) RU2450813C2 (id)
SG (1) SG142116A1 (id)
SI (2) SI1096932T1 (id)
SK (1) SK285863B6 (id)
TR (1) TR200100062T2 (id)
WO (1) WO2000002543A2 (id)
ZA (1) ZA200100232B (id)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
TR200805275T2 (tr) * 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
CN1172719C (zh) * 1999-04-28 2004-10-27 武田药品工业株式会社 单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂
EP1197226B1 (en) * 1999-07-21 2007-11-21 Takeda Pharmaceutical Company Limited Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
BR0013704A (pt) 1999-08-30 2002-05-07 Aventis Pharma Gmbh Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
AU2001235364A1 (en) 2000-02-25 2001-09-03 Novo-Nordisk A/S Tetrahydronaphtalene derivatives and their use
WO2001062740A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
HUP0301335A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
BR0108823A (pt) * 2000-12-29 2002-12-10 Osmotica Corp Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
DK1628663T3 (da) 2003-05-15 2010-03-08 Roskamp Res Llc Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
CA2525665A1 (en) * 2003-05-16 2004-11-25 Novartis Ag Pharmaceutical composition comprising valsartan
RU2255740C2 (ru) * 2003-07-02 2005-07-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
WO2006109164A2 (en) 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
RU2008122712A (ru) * 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2329805C2 (ru) * 2006-08-28 2008-07-27 Илья Николаевич Медведев Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
RU2338527C1 (ru) * 2007-02-26 2008-11-20 Илья Николаевич Медведев Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом
JP5411145B2 (ja) 2007-10-05 2014-02-12 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド （−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法
CN101433536A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和沙坦类药物的治疗组合物
MX2010007281A (es) * 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
WO2010006103A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
RU2398581C1 (ru) * 2009-05-28 2010-09-10 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) Способ лечения больных гипертрофической кардиомиопатией
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EA024096B1 (ru) * 2011-04-12 2016-08-31 Борюн Фармасьютикал Ко., Лтд. Противогипертоническая фармацевтическая композиция
AR089645A1 (es) 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica
JPWO2013147137A1 (ja) * 2012-03-30 2015-12-14 味の素株式会社 心不全の治療剤
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
US20180071272A1 (en) * 2014-10-23 2018-03-15 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
RU2616213C2 (ru) * 2015-07-10 2017-04-13 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
CN108289958A (zh) * 2015-10-31 2018-07-17 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
CN105287550A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种缬沙坦/非洛地平复方制剂及其制备方法
WO2021211944A1 (en) 2020-04-17 2021-10-21 Honeybrains, Llc Compositions and methods for treating neuropsychiatric disorders
WO2021239106A1 (zh) * 2020-05-28 2021-12-02 杭州起岸生物科技有限公司 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
PH30484A (en) * 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
WO1993017682A1 (en) * 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5599559A (en) * 1992-07-27 1997-02-04 Pfizer Inc. Calcium channel blocking polypeptide from agelenopsis aperta and therapeutic methods employing it
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
CA2181461A1 (en) * 1994-02-08 1995-08-17 Alica Huxley Treatment of normotensive glaucoma with angiotensin ii antagonists
FI963611A7 (fi) * 1994-03-17 1996-09-13 Novartis Ag Diabeettisen munuaissairauden hoito valsartaanilla
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos

Also Published As

Publication number Publication date
PL194604B1 (pl) 2007-06-29
PT1096932E (pt) 2007-09-21
HK1036758A1 (en) 2002-01-18
HK1152897A1 (en) 2012-03-16
IL213926A0 (en) 2011-07-31
HUP0102828A3 (en) 2002-11-28
ID27664A (id) 2001-04-19
NO20010113L (no) 2001-03-09
SG142116A1 (en) 2008-05-28
CZ299429B6 (cs) 2008-07-23
DE122007000055I1 (de) 2007-12-13
WO2000002543A3 (en) 2000-06-29
ES2289814T3 (es) 2008-02-01
NL300290I2 (nl) 2008-11-03
CY2007026I1 (el) 2009-11-04
NO20010113D0 (no) 2001-01-08
CZ200187A3 (en) 2001-05-16
EP1870098A3 (en) 2010-07-07
JP2002520274A (ja) 2002-07-09
EP1870098A2 (en) 2007-12-26
NZ509260A (en) 2003-09-26
CY1107779T1 (el) 2010-07-28
WO2000002543A2 (en) 2000-01-20
HU229383B1 (en) 2013-11-28
KR20040078140A (ko) 2004-09-08
CY2016006I1 (el) 2016-10-05
HUP0102828A2 (hu) 2002-04-29
AU5034999A (en) 2000-02-01
SI2322174T1 (sl) 2015-12-31
NO2012013I2 (no) 2014-10-27
DE69936992T2 (de) 2008-03-06
PL345897A1 (en) 2002-01-14
CN1234357C (zh) 2006-01-04
RU2243768C2 (ru) 2005-01-10
CA2678722C (en) 2013-08-27
NO2012013I1 (no) 2012-07-30
TR200100062T2 (tr) 2001-06-21
NO331802B1 (no) 2012-04-10
EP2322174B1 (en) 2015-09-23
CZ304359B6 (cs) 2014-03-26
SK312001A3 (en) 2001-06-11
RU2012110522A (ru) 2013-09-27
RU2450813C2 (ru) 2012-05-20
SK285863B6 (sk) 2007-10-04
DK1096932T3 (da) 2007-10-15
CN1312715A (zh) 2001-09-12
ATE371448T1 (de) 2007-09-15
CY1116770T1 (el) 2016-10-05
DK2322174T3 (en) 2015-10-12
CY2016006I2 (el) 2016-10-05
CA2336822C (en) 2009-11-17
NL300290I1 (id) 2007-11-01
NL300800I2 (id) 2016-07-27
EP2322174A3 (en) 2011-07-27
IL140665A0 (en) 2002-02-10
EP1096932B1 (en) 2007-08-29
CA2678722A1 (en) 2000-01-20
KR20010079517A (ko) 2001-08-22
LU91358I2 (fr) 2007-11-06
SI1096932T1 (sl) 2008-04-30
CA2336822A1 (en) 2000-01-20
EP1096932A2 (en) 2001-05-09
BR9912021A (pt) 2001-04-03
DE69936992D1 (de) 2007-10-11
IL140665A (en) 2012-12-31
FR16C0008I1 (id) 2016-04-15
NZ527598A (en) 2005-04-29
LU92992I2 (fr) 2016-05-09
AU753486B2 (en) 2002-10-17
EP2322174A2 (en) 2011-05-18
KR100550167B1 (ko) 2006-02-08
PT2322174E (pt) 2015-10-27
FR16C0008I2 (fr) 2018-06-08
ES2552639T3 (es) 2015-12-01
CY2007026I2 (el) 2009-11-04
CN1733307A (zh) 2006-02-15
ZA200100232B (en) 2002-04-09

Similar Documents

Publication Publication Date Title
BE2016C011I2 (id)
BE2016C025I2 (id)
EP1507558B8 (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic